360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Par Pharmaceutical

Type: Company

Name: Par Pharmaceutical

First reported May 22 2013 - Updated May 22 2013 - 1 reports

AstraZeneca PLC

Par Pharmaceutical begins shipment of generic Atacand

Par Pharmaceutical (PRX) announced that it has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca to distribute the authorized generic version of AstraZeneca's (AZN) Atacand. Par has begun shipping 4 mg, 8 mg, 16 mg and ... [Published Yahoo! Finance - May 22 2013]

Entities: Par Pharmaceutical, Atacand, AstraZeneca PLC, IMS Health Inc, Generic Version

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Santarus Inc

The Retire Young Portfolio: Time To Add A High-Growth Medicine Company

Since April 18, I have been introducing different companies to the `Retire Young` portfolio. We started out with Monster Beverages (MNST), followed by Statoil (STO), Wells Fargo (WFC), American Express (AXP), The Walt Disney Company (DIS), Hewlett-Packard ... [Published Seeking Alpha - May 22 2013]

Entities: Santarus Inc, Drugs, Portfolio, Par Pharmaceutical

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Court Report -- May 19, 2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.• Plaintiff: AbbVie Inc.• Defendants: Hetero USA Inc.; Hetero Labs Ltd.Infringement of U.S. Patent Nos. 7,148,359 ("Polymorph of a Pharmaceutical," issued ... [Published JD Supra - May 20 2013]

Entities: Endo Pharmaceuticals Holdings Incorporated, Generic Version, Par Pharmaceutical, Par Pharmaceutical Companies Inc, Infringement

First reported May 14 2013 - Updated May 14 2013 - 2 reports

FDA Food & Drug Administration

IntelGenx Technologies loses $500,000 in Q1 2013

IntelGenx Technologies Corp. has released financial results for the quarter ended March 31, 2013, and has provided an update on operational developments."The first quarter of 2013 was another busy period at IntelGenx with the recruitment of Dr. Rajiv ... [Published Stockwatch - May 14 2013]

Entities: IntelGenx Technologies Corp, New Drug Application, Par Pharmaceutical, FDA Food & Drug Administration, Antihypertensive Drug

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Par Pharmaceutical to Host 1Q Conference Call

Par Pharmaceutical Companies, Inc. announced that it will host a conference call on Thursday, May 16, at 10 a.m. EDT to review its results of operations for the quarter ended March 31, in a release. ((Comments on this story may be sent to newsdesk@cl ... [Published Individual.com - May 13 2013]

Entities: Par Pharmaceutical, Par Pharmaceutical Companies Inc

First reported May 08 2013 - Updated May 09 2013 - 4 reports

Par Pharmaceutical, Inc. Announces Quarterly Conference Call

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!WOODCLIFF LAKE, N.J. , May 8, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. announced today that it will host... ... [Published BioSpace - May 09 2013]

Entities: Par Pharmaceutical, Par Pharmaceutical Companies Inc

First reported May 06 2013 - Updated May 06 2013 - 1 reports

The Medicines Company

Court Report - May 05, 2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.Eisai R&D Management Co., Ltd. v. ReaReview and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. ... [Published JD Supra - May 06 2013]

Entities: The Medicines Company, Patent, Apotex

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Par Pharmaceutical Companies, Inc.: Pharmaceuticals and Healthcare - Company Profile and SWOT Report - new company profile report

contains in depth information and data about the company and its operations. The profile contains a company overview, key facts,major products and services, swot analysis, business description, company history, mergers and acquisitions, recent developments, ... [Published TransWorldNews - May 06 2013]

Entities: Par Pharmaceutical Companies Inc, Par Pharmaceutical, Health Care, Drugs, Key Employees

First reported May 01 2013 - Updated May 01 2013 - 1 reports

New Jersey is Paid $600,000-Plus from Separate Settlements R. . .

New Jersey is Paid $600,000-Plus from Separate Settlements Resolving Allegations of Wrongdoing by Two Pharmaceutical ManufacturersTargeted News ServiceTRENTON, N.J., April 30 -- The New Jersey Attorney General issued the following news release:Attorney ... [Published Equities.com - May 01 2013]

Entities: Par Pharmaceutical, Megace, Megestrol acetate, Drugs, Aranesp

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Par Pharmaceutical Nabbed: Put Older Patients At Risk With Weight-Gain Drug Megace ES

Play fun games to keep your brain strong and have a chance to win $25,000! See official rules.More on Drug SafetyDrug company put elderly at risk with off-label marketing of Megace ES. — Randy Faris/CorbisFor nearly eight years, New Jersey-based Par Pharmaceutical ... [Published AARP - Apr 30 2013]

Entities: Megace, Par Pharmaceutical, Patient, Drugs

First reported Mar 22 2013 - Updated Mar 22 2013 - 1 reports

TAMSULOSIN HYDROCHLORIDEcapsule [Par Pharmaceutical Inc.]

Updated Date: Mar 22, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2013]

Entities: Tamsulosin, Par Pharmaceutical

First reported Feb 14 2013 - Updated Feb 15 2013 - 2 reports

LAMOTRIGINE EXTENDED RELEASEtablet [Par Pharmaceutical Inc.]

Updated Date: Feb 7, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 15 2013]

Entities: Par Pharmaceutical, lamotrigine

Quotes

Dr. Rajiv Khosla added, "I want to thank Horst and the rest of the board of directors for the opportunity to join the IntelGenx team. Our portfolio of drug delivery technologies could make the company the drug delivery company of choice in the industry"

IntelGenx Technologies loses $500,000 in Q1 2013 [Published Stockwatch - May 14 2013]

Infringement of U S Patent Nos. 7,582,727 ( "Pharmaceutical Formulations of Bivalirudin and Process of Making the Same" issued September 1, 2009) and 7,598,343 (same title, issued October 6, 2009) following a Paragraph IV certification as part of Apotex's filing of an...

Court Report - May 05, 2013 [Published JD Supra - May 06 2013]

...llegations exist that anyone was harmed, the Justice Department says Par was aware of the potential side effects associated with the drug, including "an increased risk of deep-vein thrombosis, toxic reactions in elderly patients with impaired renal function, and mortality."

Par Pharmaceutical Nabbed: Put Older Patients At Risk With Weight-Gain Drug Megace ES [Published AARP - Apr 30 2013]

...Horst Zerbe, president and chief executive officer of IntelGenx. "As we enter 2013, we have received payment of the $1.0-million milestone invoiced to Edgemont at the end of the fourth quarter of 2012 and we look forward to receiving royalty income from Forfivo XL whilst we pursue licensing opportunities for the rest of the world. We will also continue to focus our attention on achieving FDA approval of the remaining products in our pipeline, with a 505(b)(2) NDA submission for our anti-migraine VersaFilm product on track to be filed by the end of March 2013, as previously disclosed."

IntelGenx Tech loses $2.3-million in 2012 [Published Stockwatch - Mar 18 2013]

More Content

sort by: Date \| Relevance
Par Pharma begins shipment of candesartan cilex... [Published PharmaBiz - 3 hours ago]
The Retire Young Portfolio: Time To Add A High-... [Published Seeking Alpha - May 22 2013]
Par Pharmaceutical begins shipment of generic A... [Published Yahoo! Finance - May 22 2013]
Par Pharmaceutical Begins Shipment of Generic A... [Published PR Newswire - May 22 2013]
Court Report -- May 19, 2013 [Published JD Supra - May 20 2013]
IntelGenx Technologies loses $500,000 in Q1 2013 [Published Stockwatch - May 14 2013]
IntelGenx Reports Q1, 2013 Results and Provides... [Published Stockwatch - May 14 2013]
Par Pharmaceutical to Host 1Q Conference Call [Published Individual.com - May 13 2013]
Par Pharmaceutical, Inc. Announces Quarterly Co... [Published BioSpace - May 09 2013]
Par Pharmaceutical Announces Quarterly Conferen... [Published KHQ Right Now - May 08 2013]
Par Pharmaceutical Announces Quarterly Conferen... [Published Sacramento Bee - May 08 2013]
Par Pharmaceutical Announces Quarterly Conferen... [Published Zecco - May 08 2013]
Par Pharmaceutical Announces Quarterly Conferen... [Published PR Newswire: Health - May 08 2013]
Court Report - May 05, 2013 [Published JD Supra - May 06 2013]
Par Pharmaceutical Companies, Inc.: Pharmaceuti... [Published TransWorldNews - May 06 2013]
New Jersey is Paid $600,000-Plus from Separate ... [Published Equities.com - May 01 2013]
Par Pharmaceutical Nabbed: Put Older Patients A... [Published AARP - Apr 30 2013]
Par Pharmaceutical Companies, Inc.: Pharmaceuti... [Published MarketResearch.com - Apr 19 2013]
Eisai appoints Lynn Kramer chief clinical officer [Published PMLive - Apr 17 2013]
TRAVOPROST OPHTHALMIC SOLUTION 0.004% (Travopro... [Published DailyMed Drug Label Updates for the last seven ... - Apr 16 2013]
IntelliPharmaCeutics loses $1.34-million (U.S.)... [Published Stockwatch - Apr 03 2013]
TAMSULOSIN HYDROCHLORIDEcapsule [Par Pharmaceut... [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2013]
FLUVOXAMINE MALEATE EXTENDED-RELEASE (Fluvoxami... [Published DailyMed Drug Label Updates for the last seven ... - Mar 20 2013]
IntelGenx Tech loses $2.3-million in 2012 [Published Stockwatch - Mar 18 2013]
NASCOBAL (Cyanocobalamin) Spray [Par Pharmaceut... [Published DailyMed Drug Label Updates for the last seven ... - Mar 18 2013]
CLOMIPHENE CITRATEtablet [Par Pharmaceutical Inc] [Published DailyMed Drug Label Updates for the last seven ... - Mar 18 2013]
MEGACE ES (Megesterol Acetate) Suspension [Par ... [Published DailyMed Drug Label Updates for the last seven ... - Mar 14 2013]
Par Pharmaceutical Begins Shipment of Generic L... [Published PR Newswire: Policy & Public Interest - Mar 14 2013]
Par Pharmaceutical Announces Quarterly Conferen... [Published PR Newswire: Health - Mar 11 2013]
Manufacturer of AIDS Drug Pleads Guilty to Shad... [Published ThirdAge - Mar 07 2013]

Blogs

sort by: Date \| Relevance
TRAVOPROST OPHTHALMIC SOLUTION 0.004% (Travopro... [Published DailyMed Drug Label Updates for the last seven ... - Apr 16 2013] Updated Date: Apr 16, 2013 EST ...
TAMSULOSIN HYDROCHLORIDEcapsule [Par Pharmaceut... [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2013] Updated Date: Mar 22, 2013 EST ...
FLUVOXAMINE MALEATE EXTENDED-RELEASE (Fluvoxami... [Published DailyMed Drug Label Updates for the last seven ... - Mar 20 2013] Updated Date: Mar 20, 2013 EST ...
NASCOBAL (Cyanocobalamin) Spray [Par Pharmaceut... [Published DailyMed Drug Label Updates for the last seven ... - Mar 18 2013] Updated Date: Mar 18, 2013 EST ...
CLOMIPHENE CITRATEtablet [Par Pharmaceutical Inc] [Published DailyMed Drug Label Updates for the last seven ... - Mar 18 2013] Updated Date: Mar 18, 2013 EST ...

Press Releases

sort by: Date \| Relevance
Par Pharmaceutical Begins Shipment of Generic A... [Published PR Newswire - May 22 2013]
Par Pharmaceutical Announces Quarterly Conferen... [Published PR Newswire: Health - May 08 2013]
Par Pharmaceutical Begins Shipment of Generic L... [Published PR Newswire: Policy & Public Interest - Mar 14 2013]
Par Pharmaceutical Announces Quarterly Conferen... [Published PR Newswire: Health - Mar 11 2013]
Par Pharmaceutical Pays $45 Million To Settle W... [Published PR Newswire: Policy & Public Interest - Mar 06 2013]